www.StockMarketingInc.com: Breaking News!! SKTO aEUR" "SK3 Group Signs Joint Venture With Premier Medical Group Inc." Sign Up Fo

(PINKSHEET: SKTO - SK3 Group, Inc.)

(NASDAQ: RGNC - Regency Energy Partners LP)

(OTCBB: UNCO - Unico, Inc)

(OTCBB: CSGH - China Sun Group High-Tech Co.)

(OTCBB: IARO - International Aerospace Enterprises, Inc.)

(OTCBB: PYMX - PolyMedix, Inc.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

(PINKSHEET: SKTO - SK3 Group, Inc.)

SK3 Group Signs Joint Venture With Premier Medical Group Inc.

CARLSBAD, CALIFORNIA, Oct 28, 2009 -- SK3 Group, Inc. (PINK SHEETS: SKTO | Quote | Chart | News | PowerRating) has signed a joint venture with Premier Medical Group, Inc. (PMG) of Florida. PMG is a mobile provider of diagnostic testing, allowing the patient to have testing in a familiar environment while allowing the doctor to maintain and provide quality in-office diagnostic procedures without any of its associated complexities. The company has been in business for seventeen years and currently does over four million dollars a year in sales.

PMG offers, among other tests, Nerve Conduction Velocities, Dermatomal Somatosensory Evoked Potentials, and Spinal Ultrasounds. Additionally, insurance companies recognize NCV'S, DSEP's, Needle EMG's, and Spinal Ultrasonography as credible diagnostic tests which may allow for extended patient care. This insurance advantage, and the fact that it can provide objective documentation makes it a vital tool in today's physician's diagnostic battery.

SK3 sees this joint venture as a way to increase its service offerings and hereby increase revenues, as SK3 earns a 20% fee on every test and visit. SK3 will be aggressively marketing these services to its PEO markets and much of the long-term disability and compensation requires such testing, and SK3 already has a 27,000 client roster. SK3 will average $140 per test administered.

About SK3 Group, Inc.

SK3 Group has two divisions that provide medical related services to its customers. Nurses On-Line is a subscription service for employers who are seeking pre-screening of workers' compensation injuries by a registered nurse prior to disposition of medical treatment - first aid, clinical referral, or emergency hospital. The purpose of this service is to assist employers with managing the ongoing risk associated with workers' compensation claims and their relationship to premiums and reserves charged by insurance carriers. SK3 Group also markets preferred medical services through its facilitation partners to its PEO client base.

Corporate information can be found at http://www.sk3groupinc.com

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

(NASDAQ: RGNC - Regency Energy Partners LP)

Regency Energy Partners Announces Cash Distribution of 44.5 Cents

DALLAS, Oct 27, 2009 -- Regency Energy Partners LP (Nasdaq: RGNC) ("Regency" or the "Partnership") announced today a cash distribution of 44.5 cents per outstanding common unit for the third quarter ended September 30, 2009. The distribution will be paid on November 13, 2009, to unitholders of record at the close of business on November 6, 2009. This distribution is equivalent to $1.78 on an annual basis.

Regency will hold a quarterly conference call to discuss third-quarter 2009 results on Monday, November 9, 2009, at 10 a.m. Central Time (11 a.m. Eastern Time).

The dial-in number for the call is 1-866-788-0543 in the United States, or +1-857-350-1681 outside the United States, pass code 60157784. A live webcast of the call can be accessed on the investor information page of Regency's Web site at www.regencyenergy.com. The call will be available for replay for 7 days by dialing 1-888-286-8010 (from outside the U.S., +1-617-801-6888) pass code 20543277. A replay of the broadcast will also be available on the Partnership's Web site.

This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Please note that 100 percent of Regency's distributions to foreign investors are attributable to income that is effectively connected with a United States trade or business.

Accordingly, Regency's distributions to foreign investors are subject to federal income tax withholding at a rate of 35 percent.

This press release may contain forward-looking statements regarding Regency Energy Partners, including projections, estimates, forecasts, plans and objectives. These statements are based on management's current projections, estimates, forecasts, plans and objectives and are not guarantees of future performance. In addition, these statements are subject to certain risks, uncertainties and other assumptions that are difficult to predict and may be beyond our control. These risks and uncertainties include changes in laws and regulations impacting the gathering and processing and contract compression businesses, the level of creditworthiness of the Partnership's counterparties, the Partnership's ability to access the debt and equity markets, the Partnership's use of derivative financial instruments to hedge commodity and interest rate risks, the amount of collateral required to be posted from time to time in the Partnership's transactions, changes in commodity prices, interest rates, demand for the Partnership's services, weather and other natural phenomena, industry changes including the impact of consolidations and changes in competition, the Partnership's ability to obtain required approvals for construction or modernization of the Partnership's facilities and the timing of production from such facilities, and the effect of accounting pronouncements issued periodically by accounting standard setting boards. Therefore, actual results and outcomes may differ materially from those expressed in such forward-looking information.

In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than the Partnership has described. The Partnership undertakes no obligation to update publicly or to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Regency Energy Partners LP (Nasdaq: RGNC) is a growth-oriented, midstream energy partnership engaged in the gathering and processing, contract compression and transportation of natural gas and natural gas liquids. Regency's general partner is majority-owned by an affiliate of GE Energy Financial Services, a unit of GE (NYSE: GE). For more information, visit the Regency Energy Partners LP Web site at www.regencyenergy.com.

SOURCE: Regency Energy Partners LP

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

(OTCBB: UNCO - Unico, Inc)

LATEST NEWS!!

Unico, Inc. Announces Approval for Construction of New Tailings Pond at the Deer Trail Mine

SAN DIEGO, CA, Oct 27, 2009 -- Unico, Incorporated (OTCBB: UNCO), a natural resource company in the precious metals mining sector, today announced that the company's wholly owned Deer Trail Mining Company subsidiary has received an approval for the construction of a new tailings impoundment at the Deer Trail Mine in Marysvale, Utah. The new tailings impoundment is expected to allow for full-scale production for up to one year.

In September 2009, Deer Trail Mining Company submitted its application to acquire the necessary permits to construct the new tailings pond with the Utah Department of Environmental Quality and its regulatory agency, the Division of Water Quality, for the construction of the new tailings impoundment. Documentation regarding the planned tailings impoundment is being submitted to the Utah Division of Oil, Gas and Mining for reclamation calculations and approval. Approval for the construction of the new tailing pond was received from the Division of Water Quality several days ago.

The company anticipates construction of the tailings impoundment being completed before the end of the 2009 calendar year and put into use immediately after construction is completed.

"We are pleased to have received approval of the construction permit for the new tailings pond and appreciate the Division of Water Quality processing our application in a timely manner," said Charles Madsen, executive vice president for operations of Unico, Inc. "The new impoundment is necessary for us to keep pace with the planned increase in processing operations at the Deer Trail Mine. We look forward to initiating construction of the new pond and moving our Deer Trail project forward."

Unico, Inc. recently announced an initial agreement with Royal Mines And Minerals Corporation, which utilizes a proprietary technology for the lixiviation of precious metals, to process ore from the Deer Trail Mine. Concentrate and concentrate samples produced at the Deer Trail mill facility has been shipped to Royal Mines' Phoenix facility for the processing of gold and silver content. The purpose of this initiative is to develop the most economical process and achieve the highest possible recovery of precious metals, primarily gold and silver, from material produced at the site.

Shareholders who would like to sign up to receive information by email directly from Unico, Inc., including when newsletters are posted to the company website, are asked to visit the company's website at http://www.unicomining.com/IR/mailinglist.php and fill in the appropriate fields.

About Unico, Inc.

Unico, Inc. (OTCBB: UNCO) is a publicly traded natural resource company in the precious metals mining sector that is focused on the exploration, development and production of gold, silver, lead, zinc, and copper concentrates at its two mine properties: the Deer Trail Mine and the Silver Bell Mine. Unico and its wholly owned Deer Trail Mining Company subsidiary completed the purchase of the Deer Trail Mine in 2007, and Unico has also announced agreements to acquire over 70 additional mining claims in the area of the Deer Trail Mine including the Clyde and Crown Point mining claims. For more information, please visit www.unicomining.com.

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

(OTCBB: CSGH - China Sun Group High-Tech Co.)

LATEST NEWS!!

China Sun Group High-Tech Co. Signs LOI to Jointly Produce Finished Li-Ion Batteries for Electric Vehicles

LIAONING PROVINCE, China, Oct 27, 2009 -- China Sun Group High-Tech Co. (OTC Bulletin Board: CSGH), which through its wholly-owned subsidiary Dalian Xinyang High-Tech Development Co. Ltd. ("DLX") has the second largest cobalt series production capacity in the People's Republic of China ("PRC"), announced today that on September 27, 2009, DLX signed a Letter of Intent (LOI) with Beijing Zhongxinlian Shuangsheng Sci-Tech Co., Ltd. to jointly produce finished lithium ion (li-ion) batteries under the registered brand name "ShenKun." The 100An serial power ShenKun batteries are made with DLX's lithium iron phosphate product, an alternative, environmentally-friendly energy component.

Since DLX began production of its new li-ion product in May 2009, two of China's leading battery producers, Shandong Shengong KP-Power Co., Ltd. and Beijing Zhongxinlian Shuangsheng Sci-Tech Co., Ltd., have successfully completed testing of li-ion batteries using DLX components. The companies are now demonstrating a prototype battery to electric vehicle manufacturers to facilitate sales of finished li-ion products. In addition, China Sun Group has 21 customers undergoing technical testing of its new li-ion product.

Bin Wang, CEO of China Sun Group, said, "The goal of our strategic agreement with Beijing Zhongxinlian is to accelerate the commercialization of our green, li-ion battery product to the global electric vehicle manufacturing market. With the production of finished li-ion batteries, China Sun Group looks forward to expanding its business worldwide as a complete, end-to-end battery product manufacturer."

About China Sun Group

China Sun Group High-Tech Co., ("China Sun Group") produces anode materials used in lithium ion batteries. Through its wholly-owned operating subsidiary, Dalian Xinyang High-Tech Development Co. Ltd ("DLX"), the Company primarily produces cobaltosic oxide and lithium cobalt oxide.

According to the China Battery Industry Association, DLX has the second largest cobalt series production capacity in the People's Republic of China. Through its research and development division, DLX owns a proprietary series of nanometer technologies that supply state-of-the-art components for advanced lithium ion batteries. Leveraging its state-of-the-art technology, high-quality product line and scalable production capacity, the Company plans to create a fully integrated supply chain from the primary manufacturing of cobalt ore to finished products, including lithium ion batteries. For more information, visit http://www.china-sun.cn.

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

(OTCBB: IARO - International Aerospace Enterprises, Inc.)

LATEST NEWS!!

IAE Announces $2.45 Million USD Contract

ONTARIO, Calif., Oct 27, 2009 -- International Aerospace Enterprises, Inc. (OTCBB: IARO) today announced that the company has received a contract of $2,450,000 USD for military aircraft spare parts. The contract calls for the delivery of the parts prior to the end of this fiscal year.

John Peck, IAE's Chief Executive Officer, stated, "This contract, combined with the others announced earlier by IAE, totals $16,000,000 USD.

The $16 million in contracts have been received by IAE since the return of Saffet Uslu, IAE's President, from his Middle East trip earlier this year."

About International Aerospace Enterprises, Inc.

International Aerospace Enterprises, Inc. (OTCBB: IARO) is an innovative and aggressive provider of discounted military aircraft spare parts for U.S. Ally partners throughout the world. The company offers inexpensive and shipment ready aircraft spare parts for both military and commercial aircraft users that meet all industry standards for quality manufacturing.

Note: Certain Statements in this news release may contain forward-looking information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as 'anticipate,' 'believe,' 'expect,' 'future,' 'intend,' 'plan,' and similar expressions to identify forward-looking statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statement to reflect occurrences, developments, events, or circumstances after the date of such statement.

SOURCE: International Aerospace Enterprises, Inc.

----------------------------------------------------------------------------------------------------------------------------------------------
-------------

(OTCBB: PYMX - PolyMedix, Inc.)

LATEST NEWS!!

PolyMedix Completes Successful Phase 1B Clinical Study of Heparin Antagonist PMX-60056

PMX-60056 Heptagonist Meets Safety and Efficacy Endpoints in Reversing Effects of Heparin

RADNOR, Pa., Oct 27, 2009 -- PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056. The Phase 1B clinical study was a pilot proof-of-concept study conducted in the U.S. under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).

Highlights from the Phase 1B clinical study include:

-- PMX-60056 completely reversed the anticoagulant effects of heparin and normalized blood clotting time in human subjects in less than 10 minutes.

-- No serious adverse events occurred during the study of PMX-60056.

"We are very proud and happy to have completed this major step in the development of PMX-60056," commented Nicholas Landekic, President & Chief Executive Officer of PolyMedix. "PMX-60056 represents a new class of drug, which we call heptagonists, and we believe is the only compound being developed as a reversing agent for heparin and low molecular weight heparins (LMWHs). PMX-60056 may offer important benefits and improvements in treating the potential bleeding complications of heparin, which was targeted in this study, as well as LMWHs which we hope to investigate in future clinical studies. We hope that in the future PMX-60056 will allow physicians to continue to use heparin, the only anticoagulant currently available for open-heart surgery and kidney dialysis, with a new and unique reversing agent, and potentially the first reversing agent for LMWH's."

"I am encouraged by the promising results with PMX-60056. This drug could be an important addition to the medical armamentarium, and may address unmet clinical needs in reversing heparin as well as being potentially the first reversal agent for LMWH," commented Dr. Mark Stafford-Smith, of Duke University Medical Center, a clinical advisor to PolyMedix.

This Phase 1B clinical study evaluated subjects who received heparin followed by PMX-60056 or placebo. Significant additional clinical studies and regulatory submissions, and regulatory approvals from the FDA and other regulatory bodies, will be required before PMX-60056 could be commercially sold as a reversing agent for heparin or for LMWHs. PolyMedix is currently evaluating plans for the continued clinical development of PMX-60056. There can be no assurances that future clinical studies will be successful, that required regulatory approvals will be obtained, or that the company will be able to market and sell any products based on PMX-60056.

Mr. Landekic went on to comment: "This study represents a validation of the capabilities and efficiency of PolyMedix's structure-based drug design approach. In developing PMX-60056, we went from the very beginning of drug design to attaining a clinical efficacy endpoint while spending less than $10 million in direct costs. We attribute this efficiency realized in developing PMX-60056 to our structure-based drug design approach, and the skill of our seasoned research and development leadership."

Study Design

The pilot proof-of-concept study was conducted using a double-blind, placebo-controlled, crossover design, with six healthy human volunteer subjects. This study design and low number of subjects were intended to generate meaningful results for a pilot study at minimal cost. Twenty minutes after administration of a 70 U/kg dose of heparin, which is sufficient to produce anticoagulant activity, each of the subjects was administered, in a blinded manner, either a single dose of 0.3 mg/kg of PMX-60056 or a placebo as a 10-minute intravenous infusion. With the crossover design, each subject was dosed twice, initially with heparin and either PMX-60056 or a placebo and then, two days after the first dose, with heparin and whichever (PMX-60056 or a placebo) he did not receive in the first dose. Each subject thus acted as his own control.

The primary endpoint of the clinical study was safety, specifically whether blood pressure decreases would be mitigated by the presence of heparin, and the secondary endpoint was efficacy, as measured by blood clotting time. The desired outcomes were no clinically significant decrease in blood pressure, and rapid reversal of activated clotting time (ACT), a standard bedside blood clotting measurement, and activated partial thromboplastin time (aPTT), a more accurate laboratory measurement of blood clotting time. These blood clotting times are machine-read to ensure objective measurement.

PMX-60056 Background

Heparin and LMWH are widely used anticoagulant drugs to prevent blood clotting, the use of which has a risk of potentially serious bleeding side effects. There is currently no alternative to heparin for open-heart surgery and kidney dialysis. Protamine, the only drug approved to reverse the action of heparin, is associated with serious potential side effects, and can lead to late-onset bleeding as it disassociates from heparin. There is no approved reversing agent for LMWH. Therefore, we believe there is a substantial medical need, as well as significant market potential, for a viable alternative to protamine and a LMWH reversing agent. Preclinical studies conducted by PolyMedix and its collaborators have suggested that potential advantages of PMX-60056 over protamine may include reduced bleeding complications, reduced risk of allergic reactions, and the ability to neutralize LMWH.

PMX-60056 was designed to bind to the pentasaccharide region found on heparin and LMWH. PMX-60056 is believed to bind to heparin and LMWH through electrostatic and other interactions, to block the action of heparin and LMWH. This molecular combination is believed to persist until removed from circulation by normal processes. In previous studies conducted by PolyMedix and its collaborators, PMX-60056 has been demonstrated to reverse the action of heparin in human plasma, in isolated human whole blood, and in animal studies in rats and dogs.

Safety

No serious adverse events (SAEs) occurred during this Phase 1B clinical study of PMX-60056. No clinically significant blood pressure effects were observed in this study in the presence of heparin. There were several non-serious reports of "warmth" and/or "itching" during and shortly after the infusions, but no such effects were reported significantly beyond the 10-minute infusion time.

Efficacy

In all subjects receiving PMX-60056, there was a rapid and complete reversal of the anticoagulant action of heparin, as measured by ACT and aPTT. Each subject's minimum ACT and aPTT readings after being dosed with PMX-60056 were at or below the subject's ACT and aPTT readings prior to being dosed with heparin. The heparin reversal appeared to occur at or before the end of the 10-minute infusion of PMX-60056, suggesting that the 0.3 mg/kg dose may have been in excess of requirements for 70U/kg heparin. Furthermore, although not shown in the graph below, the reversal was permanent: there was no return of anticoagulation during the hours required for heparin's effects to decline naturally.

PolyMedix plans to host a conference call to discuss these Phase 1B results in the near future. We plan to announce the date and time of the event shortly.

About PolyMedix, Inc.

PolyMedix is a publicly traded emerging biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on non-peptide small molecule drug candidates that mimic the activity of proteins. The Company's antibiotic compounds, including PMX-30063 -- small molecule mimetics of human host-defense proteins -- have a mechanism of action distinct from those of current antibiotic drugs, a mechanism that is intended to make bacterial resistance unlikely to develop. The Company's goal is to develop these as rapidly acting antibiotics for serious systemic and local infections.

The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives topaints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's heptagonist compounds, including PMX-60056, reverse the activity of both heparin and low molecular weight heparins, with the goal of developing an antagonist drug for LMWHs, and one that is safer and easier to use than currently approved therapy for heparin. For more information, please visit PolyMedix at www.polymedix.com.

----------------------------------------------------------------------------------------------------------------------------------------------
--------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com
e-mail: info@StockMarketingInc.com
Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (SKTO) SKTO. (SKTO) has Short Term PowerRatings at TradingMarkets. Details on (SKTO) Short Term PowerRatings is available at This Link.